Concepedia

Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial

Martin A. Graham, Suresh Senan, Hernani Robin, Nils Eckhardt, Dennis Lendrem, Jeffery Hincks, Dennis Greenslade, R. Rampling, Stanley B. Kaye, Reinhard von Roemeling,

Cancer Chemotherapy and Pharmacology · 1997 · 38 citations · 16 references

DOI

Concepts

References

16

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Emil J. Freireich, E. A. Gehan, David P. Rall et al. · PubMed · 1966 · 1.4K citations

, , +14

Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors

R Rampling, Garth Cruickshank, Alexander D. Lewis et al. · International Journal of Radiation Oncology*Biology*Physics · 1994 · 300 citations

, , +14

Potential roles for preclinical pharmacology in phase I clinical trials.

Jerry M. Collins, Daniel S. Zaharko, Robert L. Dedrick et al. · PubMed · 1986 · 213 citations

, , +14

Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.

Julia Brown, Marilyn J. Lemmon · PubMed · 1990 · 182 citations

, , +16

Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.

Dorie Mj, Brown Jm · PubMed · 1993 · 145 citations

, , +15